Promore Pharma AB - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

Promore Pharma AB (Promore), formerly Pergamum AB is a biopharmaceutical company that develops peptide-based product candidates for local and topical treatment of infections and wounds. The companys pipeline products include LL-37 and PXL01 therapeutic peptides. Its PXL01 is used for the prevention of post-surgical adhesions and dermal scarring. Promores PXL01 is also used for Phase III trials on patients undergoing flexor tendon repair surgery in the hand. The companys LL-37 is used to promote wound healing in chronic leg ulcers. It provides product development, regulatory affairs, design and execution of clinical trial, and clinical development services. Promore is headquartered in Stockholm, Sweden.

Promore Pharma AB - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

It derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 4
List of Figures 4
Promore Pharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Promore Pharma AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Promore Pharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Promore Pharma AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Promore Pharma AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Promore Pharma AB, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Promore Pharma Enters into Agreement with PCG Clinical Services 10
Promore Pharma Enters into Co-Development Agreement with Cellastra 11
Pergamum And Cadila Pharma Partner To Develop Novel Antibiotics For Infections 12
Licensing Agreements 13
PharmaResearch Products Enters into Licensing Agreement with Promore Pharma 13
Promore Pharma Enters into Licensing Agreement with Transdermal Therapeutic Technologies 14
Acquisition 15
BrainsToVentures And Rosetta Capital Acquire Minority Stake In 13 Portfolio Companies Of Karolinska Development For US$34 Million 15
Promore Pharma AB - Key Competitors 18
Promore Pharma AB - Key Employees 19
Promore Pharma AB - Locations And Subsidiaries 20
Head Office 20
Recent Developments 21
Financial Announcements 21
Aug 20, 2018: Promore Pharma: Interim report January - June 2018 21
Aug 20, 2018: Promore Pharma: Interim report January June 2018 23
May 16, 2018: Promore Pharma Announce Interim report January March 2018 26
Nov 21, 2017: Promore Pharma: Interim report January September 2017 27
Aug 30, 2017: Promore Pharma: Interim report January June 2017 29
May 19, 2017: Promore Pharma: Interim report January March 2017 30
May 19, 2017: Interim report January March 2017 32
Corporate Communications 33
Apr 25, 2017: Promore Pharma elects Marianne Dicander Alexandersson as New Board Member and outlines plans for IPO 33
Other Significant Developments 34
Feb 06, 2018: Promore Pharma: Year-end report 2017 34
Appendix 36
Methodology 36
About GlobalData 36
Contact Us 36
Disclaimer 36

List Of Tables


Promore Pharma AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Promore Pharma AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Promore Pharma AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Promore Pharma AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Promore Pharma AB, Deals By Therapy Area, 2012 to YTD 2018 8
Promore Pharma AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Promore Pharma Enters into Agreement with PCG Clinical Services 10
Promore Pharma Enters into Co-Development Agreement with Cellastra 11
Pergamum And Cadila Pharma Partner To Develop Novel Antibiotics For Infections 12
PharmaResearch Products Enters into Licensing Agreement with Promore Pharma 13
Promore Pharma Enters into Licensing Agreement with Transdermal Therapeutic Technologies 14
BrainsToVentures And Rosetta Capital Acquire Minority Stake In 13 Portfolio Companies Of Karolinska Development For US$34 Million 15
Promore Pharma AB, Key Competitors 18
Promore Pharma AB, Key Employees 19

List Of Figures


Xinjiang Goldwind Science & Technology Co Ltd, Performance Chart (2013 - 2017) 31
Xinjiang Goldwind Science & Technology Co Ltd, Ratio Charts 33
Xinjiang Goldwind Science & Technology Co Ltd, Power, Deals By Year, 2012 to YTD 2018 34
Xinjiang Goldwind Science & Technology Co Ltd, Power, Deals by Type, 2012 to YTD 2018 35

Promore Pharma AB - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Promore Pharma AB (Promore), formerly Pergamum AB is a biopharmaceutical company that develops peptide-based product candidates for local and topical treatment of infections and wounds. The companys pipeline products include

USD 250 View Report

Promore Pharma - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Promore Pharma (Promore), formerly Pergamum AB is a biopharmaceutical company that develops products based on therapeutic peptides for local and topical treatment of infections and wounds. The companys products include

USD 250 View Report

Asarina Pharma AB (ASAP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Asarina Pharma AB (Asarina Pharma), formerly Umecrine Mood AB, a subsidiary of Umecrine AB, is a sepranolone product developer. The company offers discovery, development and commercialization of novel treatments for

USD 250 View Report

Xspray Pharma AB (XSPRAY) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Xspray Pharma AB (Xspray Pharma), formerly Xspray Microparticles AB, is a drug development company that develops and commercializes protein kinase inhibitors (PKI) for targeted cancer treatments. The companys drug candidates

USD 250 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available